Stay updated on GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page
- Check2 days agoChange DetectedA new revision entry, v3.3.4, was added to the Record History, replacing v3.3.3; this appears to be a minor administrative update to the page history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.3.3 was added to the page history. The HHS Vulnerability Disclosure link and Revision: v3.3.2 entry were removed from the footer.SummaryDifference0.1%

- Check31 days agoChange DetectedTwo new history entries were added (Study Status on 2025-12-15 and version 33 on 2025-12-10), and the 2025-07-30 entry was removed.SummaryDifference0.3%

- Check52 days agoChange DetectedFooter shows Revision: v3.3.2, replacing v3.2.0. This is a system version update and does not alter trial details or records.SummaryDifference0.1%

- Check60 days agoChange DetectedThe funding-delay notice on the page was removed, eliminating guidance about data currency during government funding gaps. This may reduce visibility into the page's reliability context for updates.SummaryDifference0.5%

- Check74 days agoChange DetectedBoth screenshots show the same Record History page for NCT03131908 with identical version entries and controls; any differences appear to be visual/UI adjustments rather than content updates.SummaryDifference0.1%

Stay in the know with updates to GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.